GlassScriptPhysician profile
Barakat Thabet
NPI 1184979577
$128,489.13
in general payments reported to CMS, 2019-2025
28 companies · $21K in 2025
The $21K reported for 2025 was more than what 93% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $10K · 2021: $24K · 2022: $36K · 2023: $15K · 2024: $9,628 · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25K · Food and Beverage: $8,856 · Consulting Fee: $7,818 · Travel and Lodging: $3,791 · Education: $397.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,650.00 |
| Food and Beverage | $8,855.95 |
| Consulting Fee | $7,817.50 |
| Travel and Lodging | $3,791.03 |
| Education | $396.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $82,557.35 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Glaxosmithkline, LLC. | $33,647.98 | 2020-2023 | Benlysta |
| Janssen Biotech, INC. | $4,706.40 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Amgen INC. | $3,029.93 | 2019-2025 | Tavneos, Enbrel, Otezla |
| Astrazeneca Pharmaceuticals LP | $1,120.33 | 2021-2025 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $718.92 | 2019-2025 | |
| Pfizer INC. | $524.67 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $288.12 | 2019-2024 | Strensiq |
| Lilly USA, LLC | $275.62 | 2023-2024 | Taltz |
| Ucb, INC. | $255.37 | 2023-2025 | Cimzia, Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $183.90 | 2019-2025 | Orencia |
| Fresenius Kabi USA, LLC | $169.66 | 2023-2025 | Idacio |
| Organon LLC | $163.70 | 2024-2025 | Renflexis, Hadlima |
| Aurinia Pharma U.S., INC. | $162.05 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.93 | 2019-2024 | Cyltezo, Ofev |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $133.84 | 2023 | Xpress Ent Dilation System |
| Kiniksa Pharmaceuticals International, Plc | $90.87 | 2024 | Arcalyst |
| Genentech USA, INC. | $68.43 | 2021-2024 | Actemra |
| Sobi, INC | $60.29 | 2023-2025 | |
| Radius Health, INC. | $38.75 | 2024 | Tymlos |
| Mallinckrodt Hospital Products INC. | $26.32 | 2025 | Acthar |
| Actelion Pharmaceuticals US, INC. | $24.58 | 2024 | Opsumit |
| Kiniksa Pharmaceuticals, LTD. | $21.40 | 2023 | Arcalyst |
| Kaleo, INC. | $20.23 | 2023 | Auvi-Q |
| Sandoz INC. | $18.98 | 2024 | Hyrimoz |
| Alvogen INC | $18.06 | 2023 | Teriparatide |
| Janssen Pharmaceuticals, INC | $14.28 | 2022 | |
| Depuy Synthes Sales INC. | $14.17 | 2024 | Orthovisc, Monovisc |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barakat Thabet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.